Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Apr 15, 2024 2:53pm
71 Views
Post# 35989989

RE:RE:RE:RE:Dawn Svoronos to be replaced by Frank Holler (MPC)

RE:RE:RE:RE:Dawn Svoronos to be replaced by Frank Holler (MPC)I would point out that Holler was Chair of the short-lived "Financing Committee" that brought us the IQ deal. That might affect your opinion of him.
Lee430 wrote: Well, it looks like I will now be voting for Holler, Zwick & Tea, and Nay to the rest of the BOD…Why would anyone vote for Dawn who oversaw the destruction of our Thera? and then we have Weil, another Dawn appointee who oversaw Tetra’s company bankruptcy! While I am on a roll can anyone explain to me what the heck did Molson (Another Dawn appointee) bring to the table other than that silver spoon he was born with?


Trogarzon wrote: At least he comes from an entrepreneurial background unlike our big pharma floaters or Chair and CEO.... 




<< Previous
Bullboard Posts
Next >>